The abstract is read at the publisher; the summary is JClub's.
Nondialyzable β-blockers at hemodialysis initiation are linked to lower 6-month, 1-year, and 3-year MACE risk versus dialyzable β-blockers, with hazard ratios down to 0.82.
- Why it matters: Major adverse cardiovascular events cluster in the first 6 months after starting hemodialysis, and the impact of β-blocker dialyzability on outcomes is uncertain.
- What they did: Using United States Renal Data System data, a target trial emulation classified 40,313 patients into nondialyzable versus dialyzable β-blocker exposure and used an instrumental variable with instrumental variable g-estimation.
- The result: Nondialyzable use was associated with significantly fewer MACE events at 6 months, 1 year, and 3 years (HRs 0.82, 0.85, and 0.90), including during the early high-risk 6-month period.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.